Loomis, Sayles & Company
IMMU

Loomis, Sayles & Company’s Immunomedics Inc IMMU Stock Holding History

Loomis, Sayles & Company’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-296,702
Closed -$25.2M – 847
2020
Q3 		$25.2M Sell
296,702
-201,114
-40% -$10.2M 0.04% 192
2020
Q2 		$17.6M Sell
497,816
-105,961
-18% -$3.1M 0.03% 238
2020
Q1 		$8.14M Buy
603,777
+106,040
+21% +$1.78M 0.02% 313
2019
Q4 		$10.5M Buy
+497,737
New +$8.78M 0.02% 341

Loomis, Sayles & Company's IMMU Position: Q4 2020 in Review

Loomis, Sayles & Company sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 296,702 shares — an estimated $25.2M sold.

Loomis, Sayles & Company first reported a position in IMMU in Q4 2019 and held it in 4 quarters. The position peaked at $25.2M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Loomis, Sayles & Company reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Loomis, Sayles & Company sold 296,702 Immunomedics Inc shares in Q4 2020, an estimated $25.2M.
  • Loomis, Sayles & Company first reported a position in Immunomedics Inc in Q4 2019 and held it in 4 quarters.
  • Loomis, Sayles & Company's Immunomedics Inc position peaked at $25.2M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Loomis, Sayles & Company's 13F filing for Q4 2020, filed 12 Feb 2021.